Sorafenib-triggered radiation recall dermatitis with a disseminated exanthematous reaction.
10.3857/roj.2013.31.3.171
- Author:
Dongryul OH
1
;
Hee Chul PARK
;
Ho Yeong LIM
;
Byung Chul YOO
Author Information
1. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. rophc@skku.edu
- Publication Type:Case Report
- Keywords:
Sorafenib;
Radiotherapy;
Radiation recall dermatitis
- MeSH:
Carcinoma, Hepatocellular;
Exanthema;
Follow-Up Studies;
Humans;
Niacinamide;
Phenylurea Compounds;
Phosphotransferases;
Pruritus;
Radiodermatitis;
Skin;
Thoracic Wall
- From:Radiation Oncology Journal
2013;31(3):171-174
- CountryRepublic of Korea
- Language:English
-
Abstract:
Sorafenib is a multi-targeted kinase inhibitor, which is the current standard treatment for advanced hepatocellular carcinoma (HCC). Only one case of radiation recall dermatitis (RRD) associated with sorafenib has been reported so far. Our patient with recurrent HCC was treated with palliative radiotherapy (RT) for the chest wall mass. Sorafenib at 400 mg twice daily was begun on the day following RT. On the 14th day post-RT, an erythematous patch was observed on right chest wall which matched area previously irradiated. It was consistent with RRD. Ten days later, a disseminated exanthematous rash and severe pruritus occurred. Sorafenib was stopped and an oral antihistamine was prescribed to relieve symptoms. At the 1-week follow-up after the cessation of sorafenib, all symptoms were resolved. Physicians should be alert to this recall phenomenon as it can occur both in the skin and elsewhere and the occurrence of RRD may be unpredictable.
